Stay connected! Share and follow:

Leukaemia CARE Careline

We're here to talk | 24-hours a day

08088 010 444

FREE from landlines & most major mobile networks

Banner

Imagine being diagnosed with a rare cancer and missing out on the most clinically effective treatments because they are not considered cost effective enough.

This could become reality for existing and newly diagnosed blood cancer patients because of proposed changes to the way drugs are funded for NHS patients in England – coming into effect on July 1st.

The proposed changes to the appraisal process could mean:

  • Access to many blood cancer drugs could be reduced.

Patients who are already receiving treatments affected by these policy changes will continue to do so. However, the changes could affect future treatment options for existing patients (should their current one stop working and they need a new line of treatment) as well as new patients, yet to be diagnosed.

  • Inequalities in access to rarer cancer treatment throughout the UK

Some drugs may be approved for use in Scotland or Wales but not in England, should NICE be unable to recommend them. This is already happening with some drugs, for example, ponatinib for the treatment of chronic myeloid leukaemia (CML) has reduced access in England but patients in Scotland and Wales are able to access it.

We think every blood cancer patient has a right to fair and equal access to treatment. To help ensure that UK blood cancer patients can access the most effective treatment options, join us and let’s put an end to this #CancerLottery.

This is not a lot to ask, and only what people deserve.

  • Fran-Woodcock

    Fran Woodcock

    Fran was diagnosed with chronic myeloid leukaemia (CML) in 2015. Read her story and why she’s joining the campaign.

    Read more
  • Marie-Denny

    Marie Denny

    Marie was diagnosed with chronic myeloid leukaemia (CML) in 2015. Read her story and how the proposed changes to the Cancer Drugs Fund (CDF) could affect her.

    Read more
  • Nigel-Deekes

    Nigel Deekes

    Nigel was diagnosed with chronic myeloid leukaemia (CML) in 2010. He's worried how the proposed changes to the Cancer Drugs Fund (CDF), especially for CML patients. 

    Read more

test..